Inferior vena cava diameter is associated with prognosis in patients with chronic heart failure independent of tricuspid regurgitation velocity
Tóm tắt
A high, Doppler-derived, tricuspid regurgitation velocity (TRV) indicates pulmonary hypertension, which may contribute to right ventricular dysfunction and worsening tricuspid regurgitation leading to systemic venous congestion, reflected by an increase in inferior vena cava (IVC) diameter. We hypothesized that venous congestion rather than pulmonary hypertension would be more strongly associated with prognosis. 895 patients with chronic heart failure (CHF) (median (25th and 75th centile) age 75 (67–81) years, 69% men, LVEF 44 (34–55)% and NT-proBNP 1133 (423–2465) pg/ml) were enrolled. Compared to patients with normal IVC (< 21 mm) and TRV (≤ 2.8 m/s; n = 504, 56%), those with high TRV but normal IVC (n = 85, 9%) were older, more likely to be women and to have LVEF ≥ 50%, whilst those with dilated IVC but normal TRV (n = 142, 16%) had more signs of congestion and higher NT-proBNP. Patients (n = 164, 19%) with both dilated IVC and high TRV had the most signs of congestion and the highest NT-proBNP. During follow-up of 860 (435–1121) days, 239 patients died. Compared to those with both normal IVC and TRV (reference), patients with high TRV but normal IVC did not have a significantly increased mortality (HR: 1.41; CI: 0.87–2.29; P = 0.16). Risk was higher for patients with a dilated IVC but normal TRV (HR: 2.51; CI: 1.80–3.51; P < 0.001) or both a dilated IVC and elevated TRV (HR: 3.27; CI: 2.40–4.46; P < 0.001). Amongst ambulatory patients with CHF, a dilated IVC is more closely associated with an adverse prognosis than an elevated TRV.
Tài liệu tham khảo
Cleland JGF, Pfeffer MA, Clark AL, Januzzi JL, McMurray JJV, Mueller C, Pellicori P, Richards M, Teerlink JR, Zannad F, Bauersachs J (2021) The struggle towards a Universal Definition of Heart Failure-how to proceed? Eur Heart J 42(24):2331–2343. https://doi.org/10.1093/eurheartj/ehab082
Pellicori P, Cleland JG, Zhang J, Kallvikbacka-Bennett A, Urbinati A, Shah P, Kazmi S, Clark AL (2016) Cardiac dysfunction, congestion and loop diuretics: their relationship to prognosis in heart failure. Cardiovasc Drugs Ther 30(6):599–609. https://doi.org/10.1007/s10557-016-6697-7
Gheorghiade M, Filippatos G, De Luca L, Burnett J (2006) Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. Am J Med 119(12 Suppl 1):S3–S10. https://doi.org/10.1016/j.amjmed.2006.09.011
Pellicori P, Platz E, Dauw J, Ter Maaten JM, Martens P, Pivetta E, Cleland JGF, McMurray JJV, Mullens W, Solomon SD, Zannad F, Gargani L, Girerd N (2021) Ultrasound imaging of congestion in heart failure: examinations beyond the heart. Eur J Heart Fail 23(5):703–712. https://doi.org/10.1002/ejhf.2032
Cuthbert JJ, Pellicori P, Flockton R, Kallvikbacka-Bennett A, Khan J, Rigby AS, Girerd N, Zannad F, Cleland JGF, Clark AL (2021) The prevalence and clinical associations of ultrasound measures of congestion in patients at risk of developing heart failure. Eur J Heart Fail 23(11):1831–1840. https://doi.org/10.1002/ejhf.2353
Berlin DA, Bakker J (2015) Starling curves and central venous pressure. Crit Care 19(1):55. https://doi.org/10.1186/s13054-015-0776-1
Damy T, Goode KM, Kallvikbacka-Bennett A, Lewinter C, Hobkirk J, Nikitin NP, Dubois-Randé JL, Hittinger L, Clark AL, Cleland JG (2010) Determinants and prognostic value of pulmonary arterial pressure in patients with chronic heart failure. Eur Heart J 31(18):2280–2290. https://doi.org/10.1093/eurheartj/ehq245
Lindenfeld J, Zile MR, Desai AS, Bhatt K, Ducharme A, Horstmanshof D, Krim SR, Maisel A, Mehra MR, Paul S, Sears SF, Sauer AJ, Smart F, Zughaib M, Castaneda P, Kelly J, Johnson N, Sood P, Ginn G, Henderson J, Adamson PB, Costanzo MR (2021) Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. Lancet 398(10304):991–1001. https://doi.org/10.1016/S0140-6736(21)01754-2
Farber HW, Foreman AJ, Miller DP, McGoon MD (2011) REVEAL registry: correlation of right heart catheterization and echocardiography in patients with pulmonary arterial hypertension. Congest Heart Fail 17(2):56–64. https://doi.org/10.1111/j.1751-7133.2010.00202.x
Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Rådegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, Rosenkranz S (2022) ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J ehac237. https://doi.org/10.1093/eurheartj/ehac237
Pellicori P, Carubelli V, Zhang J, Castiello T, Sherwi N, Clark AL, Cleland JG (2013) IVC diameter in patients with chronic heart failure: relationships and prognostic significance. JACC Cardiovasc Imaging 6(1):16–28. https://doi.org/10.1016/j.jcmg.2012.08.012
Ivey-Miranda JB, Wetterling F, Gaul R, Sheridan S, Asher JL, Rao VS, Maulion C, Mahoney D, Mebazaa A, Gray AP, Burkhoff D, Cowie MR, Cox ZL, Butler J, Fudim M, McDonald K, Damman K, Borlaug BA, Testani JM (2022) Changes in inferior vena cava area represent a more sensitive metric than changes in filling pressures during experimental manipulation of intravascular volume and tone. Eur J Heart Fail 24(3):455–462. https://doi.org/10.1002/ejhf.2395
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine SA, Authors/Task Force Members, ESC Scientific Document Group (2022) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 24(1):4–131. https://doi.org/10.1002/ejhf.2333
Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 16(3):233–270. https://doi.org/10.1093/ehjci/jev014. (Erratum.In:EurHeartJCardiovascImaging.2016Apr;17(4):412.Erratumin:EurHeartJCardiovascImaging.2016Sep;17(9):969)
Pellicori P, Kallvikbacka-Bennett A, Khaleva O, Carubelli V, Costanzo P, Castiello T, Wong K, Zhang J, Cleland JG, Clark AL (2014) Global longitudinal strain in patients with suspected heart failure and a normal ejection fraction: does it improve diagnosis and risk stratification? Int J Cardiovasc Imaging 30(1):69–79. https://doi.org/10.1007/s10554-013-0310-y
Iaconelli A, Pellicori P, Caiazzo E, Rezig AOM, Bruzzese D, Maffia P, Cleland JGF (2022) Implanted haemodynamic telemonitoring devices to guide management of heart failure: a review and meta-analysis of randomised trials. Clin Res Cardiol 14:1–13. https://doi.org/10.1007/s00392-022-02104-0
Nassif ME, Qintar M, Windsor SL, Jermyn R, Shavelle DM, Tang F, Lamba S, Bhatt K, Brush J, Civitello A, Gordon R, Jonsson O, Lampert B, Pelzel J, Kosiborod MN (2021) Empagliflozin effects on pulmonary artery pressure in patients with heart failure: results from the EMBRACE-HF trial. Circulation 143(17):1673–1686. https://doi.org/10.1161/CIRCULATIONAHA.120.052503
Tran JS, Havakuk O, McLeod JM, Hwang J, Kwong HY, Shavelle D, Zile MR, Elkayam U, Fong MW, Grazette LP (2021) Acute pulmonary pressure change after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction. ESC Heart Fail. 8(2):1706–1710. https://doi.org/10.1002/ehf2.13225
Ilyas F, Jones L, Tee SL, Horsfall M, Swan A, Wollaston F, Hecker T, De Pasquale C, Thomas S, Chong W, Stranks S, Mangoni AA, Selvanayagam JB, Chew DP, De Pasquale CG (2021) Acute pleiotropic effects of dapagliflozin in type 2 diabetic patients with heart failure with reduced ejection fraction: a crossover trial. ESC Heart Fail. 8(5):4346–4352. https://doi.org/10.1002/ehf2.13553
Kohan DE, Cleland JG, Rubin LJ, Theodorescu D, Barton M (2012) Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve? Life Sci 91(13–14):528–539. https://doi.org/10.1016/j.lfs.2012.07.034
Cooper TJ, Cleland JGF, Guazzi M, Pellicori P, Ben Gal T, Amir O, Al-Mohammad A, Clark AL, McConnachie A, Steine K, Dickstein K (2022) Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo-controlled multicentre trial. Eur J Heart Fail 24(7):1239–1248. https://doi.org/10.1002/ejhf.2527
Borlaug BA, Blair J, Bergmann MW, Bugger H, Burkhoff D, Bruch L, Celermajer DS, Claggett B, Cleland JGF, Cutlip DE, Dauber I, Eicher JC, Gao Q, Gorter TM, Gustafsson F, Hayward C, van der Heyden J, Hasenfuß G, Hummel SL, Kaye DM, Komtebedde J, Massaro JM, Mazurek JA, McKenzie S, Mehta SR, Petrie MC, Post MC, Nair A, Rieth A, Silvestry FE, Solomon SD, Trochu JN, Van Veldhuisen DJ, Westenfeld R, Leon MB, Shah SJ, REDUCE LAP-HF-II Investigators (2022) Latent pulmonary vascular disease may alter the response to therapeutic atrial shunt device in heart failure. Circulation 145(21):1592–1604. https://doi.org/10.1161/CIRCULATIONAHA.122.059486. (Erratum in: Circulation. 2022 Jul 26;146(4):e12)
Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, Strickland W, Neelagaru S, Raval N, Krueger S, Weiner S, Shavelle D, Jeffries B, Yadav JS (2011) Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 377(9766):658–666. https://doi.org/10.1016/S0140-6736(11)60101-3
Cleland JGF, Pellicori P (2021) To master heart failure, first master congestion. Lancet 398(10304):935–936. https://doi.org/10.1016/S0140-6736(21)01914-0
Damy T, Kallvikbacka-Bennett A, Goode K, Khaleva O, Lewinter C, Hobkirk J, Nikitin NP, Dubois-Randé JL, Hittinger L, Clark AL, Cleland JG (2012) Prevalence of, associations with, and prognostic value of tricuspid annular plane systolic excursion (TAPSE) among out-patients referred for the evaluation of heart failure. J Card Fail 18(3):216–225. https://doi.org/10.1016/j.cardfail.2011.12.003
Maron BA, Hess E, Maddox TM, Opotowsky AR, Tedford RJ, Lahm T, Joynt KE, Kass DJ, Stephens T, Stanislawski MA, Swenson ER, Goldstein RH, Leopold JA, Zamanian RT, Elwing JM, Plomondon ME, Grunwald GK, Barón AE, Rumsfeld JS, Choudhary G (2016) Association of borderline pulmonary hypertension with mortality and hospitalization in a large patient cohort: insights from the veterans affairs clinical assessment, reporting, and tracking program. Circulation 133(13):1240–1248. https://doi.org/10.1161/CIRCULATIONAHA.115.020207
Kolte D, Lakshmanan S, Jankowich MD, Brittain EL, Maron BA, Choudhary G (2018) Mild pulmonary hypertension is associated with increased mortality: a systematic review and meta-analysis. J Am Heart Assoc 7(18):e009729. https://doi.org/10.1161/JAHA.118.009729
Gundersen GH, Norekval TM, Haug HH, Skjetne K, Kleinau JO, Graven T, Dalen H (2016) Adding point of care ultrasound to assess volume status in heart failure patients in a nurse-led outpatient clinic. A randomised study. Heart 102(1):29–34. https://doi.org/10.1136/heartjnl-2015-307798
Dovancescu S, Pellicori P, Mabote T, Torabi A, Clark AL, Cleland JGF (2017) The effects of short-term omission of daily medication on the pathophysiology of heart failure. Eur J Heart Fail 19(5):643–649. https://doi.org/10.1002/ejhf.748
Tchernodrinski S, Lucas BP, Athavale A, Candotti C, Margeta B, Katz A, Kumapley R (2015) Inferior vena cava diameter change after intravenous furosemide in patients diagnosed with acute decompensated heart failure. J Clin Ultrasound 43(3):187–193. https://doi.org/10.1002/jcu.22173
Jhund PS, McMurray JJ, Davie AP (2000) The acute vascular effects of frusemide in heart failure. Br J Clin Pharmacol 50(1):9–13. https://doi.org/10.1046/j.1365-2125.2000.00219.x
Arvig MD, Laursen CB, Jacobsen N, Gæde PH, Lassen AT (2022) Monitoring patients with acute dyspnea with serial point-of-care ultrasound of the inferior vena cava (IVC) and the lungs (LUS): a systematic review. J Ultrasound. https://doi.org/10.1007/s40477-021-00622-7
Pellicori P, Shah P, Cuthbert J, Urbinati A, Zhang J, Kallvikbacka-Bennett A, Clark AL, Cleland JGF (2019) Prevalence, pattern and clinical relevance of ultrasound indices of congestion in outpatients with heart failure. Eur J Heart Fail 21(7):904–916. https://doi.org/10.1002/ejhf.1383
Zymliński R, Dierckx R, Biegus J, Vanderheyden M, Bartunek J, Ponikowski P (2022) Novel IVC Doraya Catheter provides congestion relief in patients with acute heart failure. JACC Basic Transl Sci 7(3):326–327. https://doi.org/10.1016/j.jacbts.2022.02.013.PMID:35411326;PMCID:PMC8993904
Jobs A, Vonthein R, König IR, Schäfer J, Nauck M, Haag S, Fichera CF, Stiermaier T, Ledwoch J, Schneider A, Valentova M, von Haehling S, Störk S, Westermann D, Lenz T, Arnold N, Edelmann F, Seppelt P, Felix S, Lutz M, Hedwig F, Borggrefe M, Scherer C, Desch S, Thiele H (2020) Inferior vena cava ultrasound in acute decompensated heart failure: design rationale of the CAVA-ADHF-DZHK10 trial. ESC Heart Fail. ESC Heart Fail. 7(3):973–983. https://doi.org/10.1002/ehf2.12598